Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N5HJ
|
|||
| Former ID |
DAP001374
|
|||
| Drug Name |
Enalaprilat
|
|||
| Synonyms |
EAL; Enalaprilate; Enalaprilatum; ENALAPRILAT INHIBITOR; Enalapril acid; Enalapril diacid; Enalaprilat anhydrous; Enalaprilic acid; Enalprilat hydrate; Enalprilate hydrate; Enalaprilat (USP); MK-422; Vasotec I.V.; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline-water (1/2); (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid; (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid dihydrate; 1-((2S)-2-{[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO}PROPANOYL)-L-PROLINE; 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Merck & Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H24N2O5
|
|||
| Canonical SMILES |
CC(C(=O)N1CCCC1C(=O)O)NC(CCC2=CC=CC=C2)C(=O)O
|
|||
| InChI |
1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1
|
|||
| InChIKey |
LZFZMUMEGBBDTC-QEJZJMRPSA-N
|
|||
| CAS Number |
CAS 76420-72-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
13885, 7887268, 11688562, 14876097, 14900718, 26719866, 26758015, 39459536, 46386741, 49681611, 50070755, 50466382, 92308386, 92308980, 93166910, 93311012, 93577953, 99313641, 103179234, 104253291, 114004069, 118313442, 121362057, 124659029, 124757412, 124800027, 125164216, 126650398, 128562671, 131325846, 134221872, 135012534, 137024395, 143297080, 144076246, 151979549, 152031989, 160661062, 160846356, 162176890, 162262134, 163564990, 164786777, 165698333, 172080415, 172913628, 175266379, 176484234, 176484707, 178102950
|
|||
| ChEBI ID |
CHEBI:4786
|
|||
| ADReCS Drug ID | BADD_D00768 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin-converting enzyme (ACE) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Renin-angiotensin system | |||
| Chagas disease (American trypanosomiasis) | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | ACE Inhibitor Pathway | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6332). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.